The Mechanical Hemolysis Assay is an in vitro test used to assess the potential for red blood cell damage by comparing the hemolytic effects of test articles with a reference device to determine their compatibility with blood contact.
NAMSA announced today its nearing acquisition of Medanex Clinic, a Belgium-based European preclinical research organization. Medanex’s robust preclinical capabilities and expertise, specifically in the Cardiovascular arena, will help enhance NAMSA capabilities and over Client experience.
Identifying the right model for a preclinical study can be a significant challenge. The choice often comes down to whether the model shares specific anatomical characteristics with the humans who will eventually be the end users of a particular medical device. Another consideration is the size of the model and how it accommodates a specific medical device.
NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Minneapolis-based American Preclinical Services (APS), a full service preclinical CRO. This purchase follows NAMSA’s acquisition of New York-based Syntactx, a leading clinical research services CRO, in January 2021.